Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy
- PMID: 17526993
- DOI: 10.1253/circj.71.936
Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy
Abstract
Background: Sustained tachycardia causes left ventricular (LV) systolic dysfunction leading to heart failure (HF), which is widely known as "tachycardia-induced cardiomyopathy (TIC)", but its prevalence and prognosis in Japanese remain unclear.
Methods and results: Of 213 consecutive patients with HF associated with atrial fibrillation (AF) requiring hospitalization (n=213) between January 1999 and December 2004, and 104 (83 males, 67+/-12.6 years) were identified as not having any structural heart disease. Of them 41 (39%) had a normal LV ejection fraction (LVEF) at the initial admission, and the remaining patients fell into 2 groups: those with rapid (<6 months) normalization of the LVEF after AF management (presumed TIC, 30 patients, 29%) and those with persistent LV systolic dysfunction (dilated cardiomyopathy (DCM), 33 patients, 32%). Although the B-type natriuretic peptide value and LVEF did not differ between the 2 groups, the LV size on admission was significantly smaller in the TIC group (LV end-diastolic dimension (LVDd) 57.6+/-7.2, LV end-systolic dimension (LVDs) 49.4+/-8.0) than in the DCM group (LVDd 63.4 +/-8.8, LVDs 55.3+/-9.6, p<0.05). During a follow-up period of 42.1+/-21.2 months, cardiac death and recurrent HF hospitalization were significantly less frequent in the TIC group than in the DCM group.
Conclusions: In AF-associated HF requiring hospitalization, TIC is the presumed cause in approximately one-third of patients without any previously known structural heart disease. That particular group is characterized by a relatively smaller LV and better prognosis under medical treatment.
Similar articles
-
Reversible cardiomyopathy after radiofrequency ablation of 30-year persistent atrial tachycardia.BMJ Case Rep. 2013 Dec 10;2013:bcr2013008727. doi: 10.1136/bcr-2013-008727. BMJ Case Rep. 2013. PMID: 24326427 Free PMC article.
-
Predicting factors for omitting beta-blockers in patients with tachycardia-induced cardiomyopathy after successful catheter ablation for atrial fibrillation.Heart Vessels. 2024 Aug;39(8):706-713. doi: 10.1007/s00380-024-02385-7. Epub 2024 Mar 6. Heart Vessels. 2024. PMID: 38446171
-
Characterisation of patients who develop atrial fibrillation-induced cardiomyopathy.Open Heart. 2024 Nov 27;11(2):e002955. doi: 10.1136/openhrt-2024-002955. Open Heart. 2024. PMID: 39608861 Free PMC article.
-
Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.J Am Coll Cardiol. 1997 Mar 15;29(4):709-15. doi: 10.1016/s0735-1097(96)00592-x. J Am Coll Cardiol. 1997. PMID: 9091514 Review.
-
How arrhythmias weaken the ventricle: an often underestimated vicious cycle.Herz. 2023 Mar;48(2):115-122. doi: 10.1007/s00059-022-05158-y. Epub 2023 Jan 25. Herz. 2023. PMID: 36695877 Review. English.
Cited by
-
Atrial fibrillation in heart failure.Curr Heart Fail Rep. 2012 Dec;9(4):309-18. doi: 10.1007/s11897-012-0108-6. Curr Heart Fail Rep. 2012. PMID: 22864857 Review.
-
Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy.Anatol J Cardiol. 2019 Feb;21(2):98-106. doi: 10.14744/AnatolJCardiol.2019.60687. Anatol J Cardiol. 2019. PMID: 30833535 Free PMC article. No abstract available.
-
Pathophysiology, diagnosis and treatment of tachycardiomyopathy.Heart. 2017 Oct;103(19):1543-1552. doi: 10.1136/heartjnl-2016-310391. Epub 2017 Aug 30. Heart. 2017. PMID: 28855272 Free PMC article. Review. No abstract available.
-
A Case of Non-Tachycardic Atrial Fibrillation Whose Left Ventricular Systolic Dysfunction Improved After Catheter Ablation.J Clin Med Res. 2023 May;15(5):274-278. doi: 10.14740/jocmr4908. Epub 2023 May 31. J Clin Med Res. 2023. PMID: 37303466 Free PMC article.
-
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.Cardiovasc Drugs Ther. 2023 Dec;37(6):1205-1223. doi: 10.1007/s10557-022-07334-y. Epub 2022 Mar 31. Cardiovasc Drugs Ther. 2023. PMID: 35357604 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous